vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and Revolve Group, Inc. (RVLV). Click either name above to swap in a different company.
Revolve Group, Inc. is the larger business by last-quarter revenue ($324.4M vs $180.9M, roughly 1.8× AVANOS MEDICAL, INC.). Revolve Group, Inc. runs the higher net margin — 5.7% vs -0.7%, a 6.4% gap on every dollar of revenue. On growth, Revolve Group, Inc. posted the faster year-over-year revenue change (10.4% vs 0.7%). AVANOS MEDICAL, INC. produced more free cash flow last quarter ($21.3M vs $-13.3M). Over the past eight quarters, Revolve Group, Inc.'s revenue compounded faster (9.5% CAGR vs 4.4%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
Revolve Theatre Company is a Henley-on-Thames based theatre company specialising in political and Shakespearean plays. The company is owned by Oliver Dench, Joe Morris and Tom Smith.
AVNS vs RVLV — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $324.4M |
| Net Profit | $-1.3M | $18.6M |
| Gross Margin | 47.5% | 53.3% |
| Operating Margin | 1.4% | 6.3% |
| Net Margin | -0.7% | 5.7% |
| Revenue YoY | 0.7% | 10.4% |
| Net Profit YoY | 99.7% | 50.4% |
| EPS (diluted) | $-0.02 | $0.27 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $180.9M | $324.4M | ||
| Q3 25 | $177.8M | $295.6M | ||
| Q2 25 | $175.0M | $309.0M | ||
| Q1 25 | $167.5M | $296.7M | ||
| Q4 24 | $179.6M | $293.7M | ||
| Q3 24 | $170.4M | $283.1M | ||
| Q2 24 | $171.7M | $282.5M | ||
| Q1 24 | $166.1M | $270.6M |
| Q4 25 | $-1.3M | $18.6M | ||
| Q3 25 | $-1.4M | $21.2M | ||
| Q2 25 | $-76.8M | $10.2M | ||
| Q1 25 | $6.6M | $11.8M | ||
| Q4 24 | $-397.3M | $12.3M | ||
| Q3 24 | $4.3M | $11.0M | ||
| Q2 24 | $1.8M | $15.4M | ||
| Q1 24 | $-900.0K | $10.9M |
| Q4 25 | 47.5% | 53.3% | ||
| Q3 25 | 48.4% | 54.6% | ||
| Q2 25 | 52.6% | 54.1% | ||
| Q1 25 | 53.6% | 52.0% | ||
| Q4 24 | 54.6% | 52.5% | ||
| Q3 24 | 54.5% | 51.2% | ||
| Q2 24 | 55.7% | 54.0% | ||
| Q1 24 | 57.1% | 52.3% |
| Q4 25 | 1.4% | 6.3% | ||
| Q3 25 | 0.1% | 7.1% | ||
| Q2 25 | -42.6% | 5.8% | ||
| Q1 25 | 6.1% | 5.0% | ||
| Q4 24 | -233.0% | 3.9% | ||
| Q3 24 | 7.0% | 5.0% | ||
| Q2 24 | 3.7% | 5.8% | ||
| Q1 24 | 2.4% | 3.4% |
| Q4 25 | -0.7% | 5.7% | ||
| Q3 25 | -0.8% | 7.2% | ||
| Q2 25 | -43.9% | 3.3% | ||
| Q1 25 | 3.9% | 4.0% | ||
| Q4 24 | -221.2% | 4.2% | ||
| Q3 24 | 2.5% | 3.9% | ||
| Q2 24 | 1.0% | 5.4% | ||
| Q1 24 | -0.5% | 4.0% |
| Q4 25 | $-0.02 | $0.27 | ||
| Q3 25 | $-0.03 | $0.29 | ||
| Q2 25 | $-1.66 | $0.14 | ||
| Q1 25 | $0.14 | $0.16 | ||
| Q4 24 | $-8.64 | $0.18 | ||
| Q3 24 | $0.09 | $0.15 | ||
| Q2 24 | $0.04 | $0.21 | ||
| Q1 24 | $-0.02 | $0.15 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $292.3M |
| Total DebtLower is stronger | $90.3M | — |
| Stockholders' EquityBook value | $778.2M | $512.5M |
| Total Assets | $1.1B | $765.0M |
| Debt / EquityLower = less leverage | 0.12× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.8M | $292.3M | ||
| Q3 25 | $70.5M | $315.4M | ||
| Q2 25 | $90.3M | $310.7M | ||
| Q1 25 | $97.0M | $300.8M | ||
| Q4 24 | $107.7M | $256.6M | ||
| Q3 24 | $89.0M | $252.8M | ||
| Q2 24 | $92.2M | $244.7M | ||
| Q1 24 | $75.8M | $273.4M |
| Q4 25 | $90.3M | — | ||
| Q3 25 | $93.4M | — | ||
| Q2 25 | $95.7M | — | ||
| Q1 25 | $98.0M | — | ||
| Q4 24 | $125.3M | — | ||
| Q3 24 | $152.6M | — | ||
| Q2 24 | $164.9M | — | ||
| Q1 24 | $167.2M | — |
| Q4 25 | $778.2M | $512.5M | ||
| Q3 25 | $778.0M | $490.2M | ||
| Q2 25 | $776.3M | $468.6M | ||
| Q1 25 | $839.4M | $453.4M | ||
| Q4 24 | $828.5M | $437.8M | ||
| Q3 24 | $1.2B | $420.8M | ||
| Q2 24 | $1.2B | $405.8M | ||
| Q1 24 | $1.2B | $389.9M |
| Q4 25 | $1.1B | $765.0M | ||
| Q3 25 | $1.1B | $751.3M | ||
| Q2 25 | $1.0B | $722.9M | ||
| Q1 25 | $1.1B | $713.9M | ||
| Q4 24 | $1.2B | $665.5M | ||
| Q3 24 | $1.7B | $670.9M | ||
| Q2 24 | $1.7B | $657.8M | ||
| Q1 24 | $1.7B | $650.0M |
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.13× | — | ||
| Q1 24 | 0.14× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $-10.2M |
| Free Cash FlowOCF − Capex | $21.3M | $-13.3M |
| FCF MarginFCF / Revenue | 11.8% | -4.1% |
| Capex IntensityCapex / Revenue | 3.8% | 1.0% |
| Cash ConversionOCF / Net Profit | — | -0.55× |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | $48.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.2M | $-10.2M | ||
| Q3 25 | $14.0M | $11.8M | ||
| Q2 25 | $6.8M | $12.6M | ||
| Q1 25 | $25.7M | $45.1M | ||
| Q4 24 | $57.9M | $3.9M | ||
| Q3 24 | $23.0M | $9.1M | ||
| Q2 24 | $27.8M | $-24.7M | ||
| Q1 24 | $-8.0M | $38.4M |
| Q4 25 | $21.3M | $-13.3M | ||
| Q3 25 | $7.0M | $7.5M | ||
| Q2 25 | $-4.2M | $10.4M | ||
| Q1 25 | $19.0M | $43.4M | ||
| Q4 24 | $53.1M | $2.1M | ||
| Q3 24 | $20.0M | $8.0M | ||
| Q2 24 | $21.9M | $-25.7M | ||
| Q1 24 | $-12.1M | $36.7M |
| Q4 25 | 11.8% | -4.1% | ||
| Q3 25 | 3.9% | 2.5% | ||
| Q2 25 | -2.4% | 3.4% | ||
| Q1 25 | 11.3% | 14.6% | ||
| Q4 24 | 29.6% | 0.7% | ||
| Q3 24 | 11.7% | 2.8% | ||
| Q2 24 | 12.8% | -9.1% | ||
| Q1 24 | -7.3% | 13.5% |
| Q4 25 | 3.8% | 1.0% | ||
| Q3 25 | 3.9% | 1.5% | ||
| Q2 25 | 6.3% | 0.7% | ||
| Q1 25 | 4.0% | 0.6% | ||
| Q4 24 | 2.7% | 0.6% | ||
| Q3 24 | 1.8% | 0.4% | ||
| Q2 24 | 3.4% | 0.4% | ||
| Q1 24 | 2.5% | 0.6% |
| Q4 25 | — | -0.55× | ||
| Q3 25 | — | 0.56× | ||
| Q2 25 | — | 1.24× | ||
| Q1 25 | 3.89× | 3.82× | ||
| Q4 24 | — | 0.32× | ||
| Q3 24 | 5.35× | 0.83× | ||
| Q2 24 | 15.44× | -1.60× | ||
| Q1 24 | — | 3.53× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
RVLV
| Fashion Apparel | $155.1M | 48% |
| Dresses | $76.4M | 24% |
| Handbags Shoes And Accessories | $67.6M | 21% |
| Beauty | $20.3M | 6% |
| Manufactured Product Other | $5.0M | 2% |
| Breakage On Store Credit And Gift Cards | $900.0K | 0% |
